HUP0002070A2 - Alternatív módon célba juttatott adenovírus - Google Patents
Alternatív módon célba juttatott adenovírusInfo
- Publication number
- HUP0002070A2 HUP0002070A2 HU0002070A HUP0002070A HUP0002070A2 HU P0002070 A2 HUP0002070 A2 HU P0002070A2 HU 0002070 A HU0002070 A HU 0002070A HU P0002070 A HUP0002070 A HU P0002070A HU P0002070 A2 HUP0002070 A2 HU P0002070A2
- Authority
- HU
- Hungary
- Prior art keywords
- adenovirus
- adenoviruses
- native
- receptor
- subject
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 239000013638 trimer Substances 0.000 abstract 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical class ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 abstract 1
- 208000010370 Adenoviridae Infections Diseases 0.000 abstract 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 abstract 1
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000005829 trimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgyát alternatív módon célba juttatott adenovírusképezi, továbbá eljárások ilyen vírusok előállítására és tisztítására,valamint ilyen alternatív célba juttatást lehetővé tevőproteinmódosítások. Közelebbről, a találmány tárgyát egy trimerrészecske képezi, amely három monomert tartalmaz, amelyek mindegyikeadenovírus-fiberprotein amino-terminusát és trimerizációs doménttartalmaz. A trimer kisebb affinitást mutat natív szubsztráttalszemben, mint a natív adenovírus fibertrimerek. A találmány tárgyátképezi továbbá, a találmány szerinti trimert tartalmazó adenovírus ésmódosított penton. Ezen felül a találmány tárgyát képezi egy olyan nemnatív sejtfelszíni receptort expresszáló sejtvonal, mely receptorhoz areceptor ligandumát hordozó adenoví-rusok kötődnek, továbbá eljárásadenovírusok szaporítására a sejtvonal alkalmazásával. A találmányszerinti megoldás alkalmas adenovírus-fertőzések kezelését ésmegelőzését célzó eljárások kidolgozására. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4784997P | 1997-05-28 | 1997-05-28 | |
US7166898P | 1998-01-16 | 1998-01-16 | |
PCT/US1998/011024 WO1998054346A1 (en) | 1997-05-28 | 1998-05-28 | Alternatively targeted adenovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0002070A2 true HUP0002070A2 (hu) | 2000-10-28 |
Family
ID=26725500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0002070A HUP0002070A2 (hu) | 1997-05-28 | 1998-05-28 | Alternatív módon célba juttatott adenovírus |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0988390A1 (hu) |
JP (1) | JP2001518806A (hu) |
BR (1) | BR9809173A (hu) |
CA (1) | CA2291323A1 (hu) |
HU (1) | HUP0002070A2 (hu) |
IL (1) | IL133010A0 (hu) |
NZ (1) | NZ501140A (hu) |
PL (1) | PL337130A1 (hu) |
SK (1) | SK159999A3 (hu) |
WO (1) | WO1998054346A1 (hu) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU767975B2 (en) * | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
WO2000046364A1 (en) * | 1999-02-05 | 2000-08-10 | The Uab Research Foundation | Fiber receptor-independent system for the propagation of adenoviral vectors |
JP2000279178A (ja) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | ウイルスベクター |
EP1593742A3 (en) * | 1999-06-01 | 2006-02-01 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection |
US7094398B1 (en) | 1999-06-01 | 2006-08-22 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
DE60018920T2 (de) * | 1999-06-01 | 2006-04-13 | University Of Washington, Seattle | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
JP5043271B2 (ja) | 2000-04-12 | 2012-10-10 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | ペプチドベースの化合物 |
CA2407518A1 (en) * | 2000-04-26 | 2001-11-01 | Crucell Holland B.V. | Adenovirus vectors with knobless fibers, and their uses |
EP1167533A1 (en) * | 2000-06-23 | 2002-01-02 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Methods and means for the complementation of viral protein expression in stable cell lines |
GB0017720D0 (en) | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
HU230901B1 (hu) | 2001-07-10 | 2019-01-28 | Ge Healthcare Limited | Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények |
FR2842823A1 (fr) * | 2002-07-25 | 2004-01-30 | Inst Nat Sante Rech Med | Adenovirus modifies pour le ciblage des lymphocytes b |
US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
EP1613757A2 (en) | 2003-03-28 | 2006-01-11 | The Scripps Research Institute | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
DE602004025726D1 (de) | 2003-11-14 | 2010-04-08 | Genvec Inc | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
EP2567967A3 (en) | 2004-04-12 | 2013-08-21 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
CA2620495A1 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
BRPI0618441B8 (pt) | 2005-11-10 | 2021-07-27 | Genvec Inc | vetor adenoviral |
WO2007094653A1 (en) * | 2006-02-13 | 2007-08-23 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles. |
WO2010075058A1 (en) | 2008-12-23 | 2010-07-01 | Ge Healthcare Limited | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
EA201270607A1 (ru) | 2009-11-09 | 2012-09-28 | Генвек, Инк. | Аденовирус обезьян и способы его использования |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
EP2654786B1 (en) | 2010-12-20 | 2019-02-20 | GenVec, Inc. | Adenoviral vector-based dengue fever vaccine |
EP2855669B1 (en) | 2012-05-29 | 2018-10-10 | GenVec, Inc. | Modified serotype 28 adenoviral vectors |
EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
EP3072900A1 (en) | 2015-03-27 | 2016-09-28 | Medizinische Hochschule Hannover | Anti-tumour medicament based on adenovirus |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
CA3038968A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851341A (en) * | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
-
1998
- 1998-05-28 BR BR9809173-5A patent/BR9809173A/pt not_active IP Right Cessation
- 1998-05-28 HU HU0002070A patent/HUP0002070A2/hu unknown
- 1998-05-28 IL IL13301098A patent/IL133010A0/xx unknown
- 1998-05-28 WO PCT/US1998/011024 patent/WO1998054346A1/en not_active Application Discontinuation
- 1998-05-28 JP JP50097799A patent/JP2001518806A/ja not_active Ceased
- 1998-05-28 NZ NZ501140A patent/NZ501140A/en unknown
- 1998-05-28 PL PL98337130A patent/PL337130A1/xx unknown
- 1998-05-28 SK SK1599-99A patent/SK159999A3/sk unknown
- 1998-05-28 EP EP98923856A patent/EP0988390A1/en not_active Withdrawn
- 1998-05-28 CA CA002291323A patent/CA2291323A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001518806A (ja) | 2001-10-16 |
WO1998054346A1 (en) | 1998-12-03 |
BR9809173A (pt) | 2000-08-01 |
EP0988390A1 (en) | 2000-03-29 |
CA2291323A1 (en) | 1998-12-03 |
NZ501140A (en) | 2001-07-27 |
IL133010A0 (en) | 2001-03-19 |
SK159999A3 (en) | 2000-06-12 |
PL337130A1 (en) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0002070A2 (hu) | Alternatív módon célba juttatott adenovírus | |
DE69637545D1 (de) | Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung | |
WO1996034107A3 (en) | Antiviral proteins, dna coding sequences therefor, and uses thereof | |
ATE328891T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen | |
IS4754A (is) | Genaferjur og aðferðir fyrir genaflutning inn í frumur | |
NO20043245L (no) | Bindingsproteiner som biosensorer | |
HUP0203567A2 (hu) | APRIL-receptor (BCMA) és alkalmazásai | |
GEP20135981B (en) | Erythropoietin receptor peptide formulations and usage thereof | |
AU2002305450A1 (en) | Proteomimetic compounds and methods | |
ATE382695T1 (de) | Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven | |
ATE421584T1 (de) | Cpg rezeptor (cpg-r) und darauf bezogene methoden | |
DE69828408D1 (de) | Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung | |
AU2002356392A1 (en) | Bone polypeptide-1 | |
PT1083903E (pt) | Indenopirrolocarbazoles em ponte | |
WO2004005481A3 (en) | Methods for identifying modulators of mda-7 mediated apoptosis | |
WO2004113500A3 (en) | B7s1: an immune modulator | |
DE60031994D1 (de) | Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung | |
HUP0100668A2 (hu) | Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk | |
FI972170A0 (fi) | Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö | |
AU2003235799A1 (en) | Modulation of iamt (pimt or pcmt) in immune system | |
DK0981601T3 (da) | Fremgangsmåder til dyrkning af celler og opformering af vira | |
DK1051491T3 (da) | Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf | |
ATE417112T1 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
TR200100430T2 (tr) | Tyrosine kinase SRC kullanılan angiogenesisin modülasyonu için yararlı metot ve bileşimler. | |
EP1073683A4 (en) | G-CSF RECEPTORAGONIST ANTIBODY AND METHOD FOR THEIR INSULATION BY MEASURING |